Ken Griffin Legend Biotech Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$43.55 - $59.88 $317,915 - $437,124	7,300 Added 33.18%	29,300 $1.43 Million
Q2 2024 Aug 14, 2024	SELL	$39.5 - $57.22 $2.99 Million - $4.33 Million	-75,700 Reduced 77.48%	22,000 $974,000
Q1 2024 May 15, 2024	BUY	$55.06 - $69.99 $2.68 Million - $3.41 Million	48,700 Added 99.39%	97,700 $5.48 Million
Q4 2023 Feb 14, 2024	BUY	$57.25 - $69.74 $2.36 Million - $2.88 Million	41,300 Added 536.36%	49,000 $2.95 Million
Q3 2023 Nov 14, 2023	SELL	$63.16 - $76.5 $31,580 - $38,250	-500 Reduced 6.1%	7,700 $517,000
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $782,132 - $1.27 Million	-16,900 Reduced 67.33%	8,200 $566,000
Q1 2023 May 15, 2023	SELL	$43.42 - $57.37 $950,898 - $1.26 Million	-21,900 Reduced 46.6%	25,100 $1.21 Million
Q4 2022 Feb 14, 2023	SELL	$38.8 - $55.46 $201,759 - $288,392	-5,200 Reduced 9.96%	47,000 $2.35 Million
Q3 2022 Nov 14, 2022	SELL	$38.15 - $57.1 $1.06 Million - $1.59 Million	-27,800 Reduced 34.75%	52,200 $2.13 Million

225

74.3M

279K

350K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.49B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.